Literature DB >> 20393460

Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.

Giacomo Salvadore1, Brian R Cornwell, Fabio Sambataro, David Latov, Veronica Colon-Rosario, Frederick Carver, Tom Holroyd, Nancy DiazGranados, Rodrigo Machado-Vieira, Christian Grillon, Wayne C Drevets, Carlos A Zarate.   

Abstract

Pregenual anterior cingulate cortex (pgACC) hyperactivity differentiates treatment responders from non-responders to various pharmacological antidepressant interventions, including ketamine, an N-methyl-D-aspartate receptor antagonist. Evidence of pgACC hyperactivition during non-emotional working memory tasks in patients with major depressive disorder (MDD) highlights the importance of this region for processing both emotionally salient and cognitive stimuli. However, it is unclear whether pgACC activity might serve as a potential biomarker of antidepressant response during working memory tasks as well, in line with previous research with emotionally arousing tasks. This study tested the hypothesis that during the N-back task, a widely used working memory paradigm, low pretreatment pgACC activity, as well as coherence between the pgACC and the amygdala, would be correlated with the clinical improvement after ketamine. Magnetoencephalography (MEG) recordings were obtained from 15 drug-free patients with MDD during working memory performance 1 to 3 days before receiving a single ketamine infusion. Functional activation patterns were analyzed using advanced MEG source analysis. Source coherence analyses were conducted to quantify the degree of long-range functional connectivity between the pgACC and the amygdala. Patients who showed the least engagement of the pgACC in response to increased working memory load showed the greatest symptomatic improvement within 4 h of ketamine administration (r=0.82, p=0.0002, false discovery rate (FDR) <0.05). Pretreatment functional connectivity between the pgACC and the left amygdala was negatively correlated with antidepressant symptom change (r=-0.73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393460      PMCID: PMC2869391          DOI: 10.1038/npp.2010.24

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  38 in total

1.  Cerebral correlates of autonomic cardiovascular arousal: a functional neuroimaging investigation in humans.

Authors:  H D Critchley; D R Corfield; M P Chandler; C J Mathias; R J Dolan
Journal:  J Physiol       Date:  2000-02-15       Impact factor: 5.182

2.  Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography.

Authors:  M Corbetta; F M Miezin; S Dobmeyer; G L Shulman; S E Petersen
Journal:  J Neurosci       Date:  1991-08       Impact factor: 6.167

3.  Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.

Authors:  A L Brody; S Saxena; D H Silverman; S Alborzian; L A Fairbanks; M E Phelps; S C Huang; H M Wu; K Maidment; L R Baxter
Journal:  Psychiatry Res       Date:  1999-10-11       Impact factor: 3.222

4.  Dynamic imaging of coherent sources: Studying neural interactions in the human brain.

Authors:  J Gross; J Kujala; M Hamalainen; L Timmermann; A Schnitzler; R Salmelin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

5.  Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression.

Authors:  Deanna M Barch; Yvette I Sheline; John G Csernansky; Abraham Z Snyder
Journal:  Biol Psychiatry       Date:  2003-03-01       Impact factor: 13.382

6.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

7.  Working-memory fMRI reveals cingulate hyperactivation in euthymic major depression.

Authors:  Sonja Schöning; Pienie Zwitserlood; Almut Engelien; Andreas Behnken; Harald Kugel; Hagen Schiffbauer; Katharina Lipina; Christine Pachur; Anette Kersting; Udo Dannlowski; Bernhard T Baune; Peter Zwanzger; Thomas Reker; Walter Heindel; Volker Arolt; Carsten Konrad
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

8.  Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.

Authors:  Kimberly Goldapple; Zindel Segal; Carol Garson; Mark Lau; Peter Bieling; Sidney Kennedy; Helen Mayberg
Journal:  Arch Gen Psychiatry       Date:  2004-01

9.  Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

Authors:  Rebecca B Price; Matthew K Nock; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2009-07-09       Impact factor: 13.382

10.  Cognitive fitness of cost-efficient brain functional networks.

Authors:  Danielle S Bassett; Edward T Bullmore; Andreas Meyer-Lindenberg; José A Apud; Daniel R Weinberger; Richard Coppola
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

View more
  89 in total

1.  A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats.

Authors:  Jing Wang; Yossef Goffer; Duo Xu; David S Tukey; D B Shamir; Sarah E Eberle; Anthony H Zou; Thomas J J Blanck; Edward B Ziff
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

2.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 3.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

4.  Psychiatric stress testing: novel strategy for translational psychopharmacology.

Authors:  Stephen M Stahl
Journal:  Neuropsychopharmacology       Date:  2010-06       Impact factor: 7.853

Review 5.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 6.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 7.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

8.  EEG power asymmetry and functional connectivity as a marker of treatment effectiveness in DBS surgery for depression.

Authors:  Maher A Quraan; Andrea B Protzner; Zafiris J Daskalakis; Peter Giacobbe; Chris W Tang; Sidney H Kennedy; Andres M Lozano; Mary P McAndrews
Journal:  Neuropsychopharmacology       Date:  2013-11-28       Impact factor: 7.853

9.  Cortical control of affective networks.

Authors:  Sunil Kumar; Sherilynn J Black; Rainbo Hultman; Steven T Szabo; Kristine D DeMaio; Jeanette Du; Brittany M Katz; Guoping Feng; Herbert E Covington; Kafui Dzirasa
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

10.  Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis.

Authors:  Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2018-10-03       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.